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period, and there was no clinical or serologic evidence of hepatic
dysfunction.
The thrombin time with human thrombin was 22.5 seconds
(upper limits of normal, 19.3 seconds). Incubation of a 1:1 mixture
of normal and patient plasma at 37°C for 1 hour prolonged both
the aPTT and PT of the normal plasma, indicating the presence of
a circulating inhibitor in the patient’s plasma. The fact that both
the PT and aPTT were prolonged suggested that the inhibitor was
against one of the coagulation factors of the common pathway (fac-
tor V, X, or II). Factor II activity was 78% (normal activity, 70% to
130%), factor X activity was 35% (normal activity, 60% to 130%),
but the factor V activity was less than 2% (normal activity, 60% to
130%). The moderate decrease in factor X activity was thought to
reflect nonspecific interference of a factor V inhibitor with the end-
point of the one stage coagulation factor assays. These coagulation
study results revealed that the patient had circulating inhibitors of
human factor V stimulated most probably by the patient’s prior
exposure to bovine thrombin. There was little cross reactivity of the
antibody with human thrombin as evidenced by the mild elevation
of the thrombin time with human thrombin in the assay. There
was, however, marked cross reactivity with human factor V that
resulted in a profound inhibition of factor V activity.
The patient did not exhibit any clinical signs of bleeding, and
at the time of discharge on postoperative day 20, the aPTT
decreased to 53 seconds and the PT decreased to 24.1 seconds
(Fig). At the 5-month follow-up examination, the patient was
doing well with a PT of 12.0 seconds, an international normal-
ized ratio of 1.1, a PTT of 29 seconds, and a factor V level of 94%.
DISCUSSION
Topical thrombin preparations are widely used in the
form of sprays, paste, fibrin glue, or other dry procoagu-
lant materials that have been soaked in the topical throm-
bin. Most of these preparations in use in the United States
are prepared from bovine thrombin.4 It is now recognized
that patients exposed to any of these preparations may
have antibodies develop to bovine thrombin, factor V, or
any other proteins that may be found in the preparations.
However, the precise clinical effects of this immunogenic
response are unclear.
Patients with repeat exposures to bovine thrombin
may have antibodies develop to the coagulation proteins
in these compounds.4 Flaherty, Henderson, and Wener5
Postoperative coagulopathy is not unusual. Causes
include supratherapeutic levels of heparin or warfarin
sodium, malnutrition, sepsis, and hypothermia.1 A less
known cause of postoperative coagulopathy is the devel-
opment of inhibitors to factor V, first described by
Ferguson, Johnson, and Howell2 in 1958. More recently,
Zehnder and Leung3 showed the development of anti-
bodies to factor V in a patient who underwent repeated
exposures to topical bovine thrombin. The authors identi-
fied the presence of factor V in commercial bovine throm-
bin and suggested that antibodies to bovine factor V
interacted with human factor V and were likely responsi-
ble for the patient’s postoperative coagulopathy.
CASE REPORT
A 75-year-old woman, who had undergone multiple lower
extremity revascularization procedures in the past, underwent
mesenteric revascularization with a bifurcated polytetrafluoroeth-
ylene graft from the supraceliac aorta. Approximately 5000 units
of bovine thrombin was used as a topical hemostatic agent in the
form of soaked gelatin sponges.
The patient’s postoperative course was initially uncompli-
cated. The daily coagulation study results routinely obtained in
our intensive care unit revealed marked elevation in the patient’s
prothrombin time (PT) and activated partial thromboplastin time
(aPTT) on the 9th postoperative day, which peaked on postoper-
ative day 11 (aPTT, 102 seconds; PT, 46.9 seconds; international
normalized ratio, 13.2; Fig). The fibrinogen level was 363
mg/dL (normal level, 193 to 383 mg/dL). The abnormal coag-
ulation parameters did not improve with the administration of vit-
amin K or fresh frozen plasma (FFP). The patient did not
undergo heparin or warfarin therapy during the postoperative
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We describe a case of severe coagulopathy after mesenteric revascularization. Laboratory investigation results revealed
the presence of plasma inhibitors of factor V believed to result from exposure to bovine thrombin used for intraoper-
ative hemostasis. Vascular and cardiothoracic surgeons commonly use topical thrombin for surgical hemostasis, and
many patients undergo multiple exposure. More patients likely have factor V inhibitors develop than has previously
been realized, and this may account for some otherwise unexplained postoperative coagulation disorders. This report
may alert surgeons to coagulation disturbances that can result from exposure to bovine thrombin and provide guide-
lines for diagnosis and management. (J Vasc Surg 2002;35:400-2.)
reported four patients with prolonged thrombin times
after surgical procedures during which topical thrombin
was used.5 Substitution of human thrombin (for the
bovine thrombin normally used in performing the throm-
bin times) normalized the clotting times, which indicated
that the inhibitor activity was directed against bovine
thrombin. Other coagulation parameters were normal in
these patients, and there were no bleeding complications.
Bleeding complications associated with antibodies to
bovine thrombin alone have not been described and are
rarely detected as thrombin times are now rarely per-
formed.
Zehnder and Leung3 reported a patient whose condi-
tion became severely coagulopathic and who had bleeding
complications after reoperative cardiac surgery with re-
exposure to topical bovine thrombin. This patient had
marked prolongation of the PT and PTT and the throm-
bin time that did not respond to administration of vitamin
K and FFP therapy. Study results of their patient revealed
the presence of an inhibitor to human factor V in addition
to the inhibitor of bovine thrombin. These investigators
were subsequently able to identify bovine factor V within
the thrombin preparations studied. The bovine factor V
was believed to stimulate the development of antibodies
that cross-reacted with human factor V and produced the
coagulopathy in their patient.
Subsequently, a number of cases of factor V inhibitors
have been described after exposure to bovine thrombin.6-8
Banninger et al6 noted the development of thrombin
inhibitors after primary exposure to bovine thrombin in
11 of 24 patients after cardiac surgery and in two of 10
patients after neurosurgical procedures. All 13 patients
with thrombin inhibitor also had significantly reduced fac-
tor V activity levels (10% to 60% of normal levels). These
authors also noted a relationship between the amount of
fibrin glue (bovine thrombin) used and the likelihood of
sensitization.
In an attempt to clarify the prevalence of these anti-
bodies, Ortel et al4 performed a prospective analysis of
151 patients who underwent cardiac surgical procedures.
They observed a 33% incidence rate of antibodies to two
or more bovine antigens in patients with likely prior expo-
sure to topical thrombin. In addition, in the postoperative
period, more than 95% of the patients had a seropositive
response to bovine coagulation proteins develop, and 51%
manifested elevated antibody levels to the corresponding
human coagulation proteins after bovine thrombin expo-
sure. The authors also found that patients with established
antibody levels to multiple bovine proteins before their
surgical procedure were more likely to have an adverse
clinical outcome after surgery.
The development of antibodies to bovine thrombin
after exposure to these products is predictable and perhaps
little more than a laboratory curiosity because thrombin
times are rarely used today. In contrast, the development
of antibodies that cross react with human factor V will
result in prolongation of both the PT and the aPTT as
seen in the case presented here. It appears that in some
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cases this finding may not simply represent a confounding
laboratory value but may be associated with a significant
clinical risk of hemorrhage. Patients who undergo vascular
surgical procedures are at higher risk for these events
because many have had prior vascular or cardiac proce-
dures in which bovine thrombin may have been used.
Appropriate mixing study and factor assay results will
identify the presence of clinically significant factor V
inhibitors. The delay in the rise in coagulation times (9
days in our patient) is caused by the time required to
develop an immune response and is consistent with other
reports.3,6 In a patient with a factor V inhibitor, invasive
procedures should be avoided because of the risk of hem-
orrhage, especially when factor V activity is less than 10%,
as in our patient. The titer of factor V inhibitors usually
falls rapidly during weeks to months in the absence of fur-
ther exposure to bovine thrombin with normalization of
the PT and aPTT.6 Although the presence of lupus-anti-
coagulant activity has been identified in some patients
with thromboembolic complications associated with the
development of anti–factor V antibodies,9 dramatic eleva-
tions of coagulation times cannot be attributed to lupus
anticoagulant alone. We recommend checking for evi-
dence of antiphospholipid antibodies in the event of
thrombotic complications.
Patients with factor V inhibitors, who have bleeding
complications and whose conditions fail to respond to FFP
administration, may undergo treatment with platelet
transfusions, intravenous gammaglobulins, and plasma-
pheresis to achieve hemostasis.3 Unfortunately, controlled
studies are lacking and the best methods of treatment
remain unclear.
Whether the incidence rate of factor V inhibitors varies
with the manufacturer of thrombin or with the delivery
technique is unclear at this time. Alternative commercial
hemostatic agents that use human thrombin and human
fibrin as fibrin glue are available. Although these products
would avoid the use of bovine thrombin, some contain
Patient international normalized ratio (INR) after surgery.
Patient was undergoing no heparin therapy in any form and no
warfarin sodium therapy and had normal hepatic function.
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bovine aprotinin as a fibrinolysis inhibitor and are con-
traindicated in individuals known to be hypersensitive to
bovine protein.
Although the magnitude of risk associated with the
presence of factor V inhibitors has been uncertain, it is
probably best that anticoagulation therapy be avoided
because factor V inhibition interferes with the PT and
aPTT assays used to monitor both warfarin sodium and
heparin anticoagulation therapy. When anticoagulation
therapy is required (eg, in patients with prosthetic heart
cardiac valves), Zumberg et al8 have suggested withhold-
ing treatment until there is a diminution in the effect of
the acquired inhibitors.
Vascular surgeons should be alerted to the possibility of
factor V inhibitors in their patients as a possible cause of
postoperative coagulopathies. Aberrations in the PT or
aPTT produced by factor V inhibitors may occur more
often than has been previously recognized. In addition,
secondary exposure in patients with unrecognized, pre-
established antibody levels has been associated with an
increased risk of surgical complication.4 Future prospective
study in patients for vascular surgery may be warranted to
establish the prevalence of significant factor V inhibitors in
patients who undergo noncardiac vascular surgical proce-
dures. The reconsideration of the routine use of these
products in our surgical procedures may also be prudent.
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